Myriad Genetics Fiscal Second Quarter 2016 Earnings Call

02/02/2016

Forward Looking Statements

Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company's annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections or forward-looking statements.

Non-GAAP Financial Measures

In this presentation, the Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company's financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company's business. A reconciliation of the GAAP to non-GAAP financial guidance is provided below.

	Fiscal Year 2016
GAAP diluted net income per share	$1.48 - $1.53
Acquisition – amortization of intangible assets	$0.15
Non-GAAP diluted net income per share	**$1.63 - $1.68**

For additional information on GAAP to non-GAAP reconciliation see:
https://www.myriad.com/investors/gaap-to-non-gaap-reconciliation/

Second Quarter Results Exceed Expectations

	Q2FY16 Actual Results	YoY Growth	Q2FY16 Company Guidance	Difference From Mid-Point
Revenue	$193.3M	5%	$188M to $190M	+$4.3M
Adjusted EPS	$0.45	13%	$0.40 to $0.42	+$0.04
GAAP EPS	$0.41	27%	$0.36 to $0.38	+$0.04

Hereditary Cancer Revenue Grows Year-Over-Year For Second Straight Quarter



Percentage of Hereditary Cancer Revenue Under Long-Term Contract Continues to Increase

% of HC Business Under LT Arrangement



Change in ASP* FY13 to 2Q16



*Average selling price

Hereditary Cancer Market Expansion Plans on Track

	Indication	Added Market Potential	Guidelines	Contracting
Oncology	Colon Cancer @ 5% Mutation Risk	+$100M	✓	50%
	All Endometrial Cancer	+$150M	✓	50%
	Breast Cancer <60 yrs	+$150M	FY16	FY17
	All Pancreatic Cancer	+$125M	FY17	FY17
Preventive Care	Colon Cancer Asymptomatic Market	+ $18B (6M patients)	✓	50%

Mutation Rate in Breast Cancer Patients Unchanged < 60 Years Old



New Product Pipeline Total Addressable and Current Reimbursed Market Opportunity



Vectra DA Volumes Grow 13% YoY



Focused on Driving Breadth and Depth of Use

Breadth of Use Among Doctors

Increased to ~50% of rheumatologists

Depth in the Patient Population Per Using Physician



11 patients tested per using physician per month (~9% of patients seen)

New Data on Predictive Ability of Vectra DA Has Reinitiated Payer Discussions

Study	Methotrexate Incomplete Responders (Hambardzumyan et al.)	Prediction of Flares in Patients Discontinuing TNFi Therapy (Lamers-Karnebeek et al.)	Prediction of Relapse in Patients Tapering DMARDs (Rech et al.)
Conclusion	"Patients with lower Vectra DA scores were more likely to respond to triple therapy, whereas patients with higher Vectra DA scores were more likely to respond to anti-TNF therapy."	"A high Vectra DA score was an independent predictor of flare within 12 months after discontinuing TNFi therapy."	"Vectra DA scores were significantly higher in RA patients relapsing than those in stable remission."
Data	157 patients; p=0.001	439 patients; p=0.03	100 patients; p=0.0034

Prolaris Volumes Grow 104% Year-Over-Year



New 2016 NCCN Guidelines on Prostate Cancer

Changes	Detail	Relevance
New recommended endpoints for validation of prognostic tests for prostate cancer	2016 NCCN guidelines list mortality, biochemical recurrence and metastases as relevant endpoints for prostate cancer prognostics	Prolaris is the only test that has been extensively validated against all of these endpoints
Change to patient management recommendations for intermediate risk patients	NCCN added some intermediate risk patients to active surveillance eligibility	Prolaris is the only prostate cancer prognostic that has been validated and has clinical utility across all risk categories

New Report Format Drives Physician Behavior Change



Urologists followed the treatment recommendations provided by the active surveillance threshold 85% of the time

Completing Reimbursement Dossier for myPath Melanoma

myPath Melanoma Diagnostic Accuracy



myPath Melanoma Clinical Utility



myChoice HRD Drives 3-Fold Increase in Pathological Complete Response in TNBC Patients



Based on a pooled analysis from five statistically significant studies comprising a total of 267 TNBC patients

*Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC); A pooled analysis.

Companion Diagnostic Portfolio Expands to Five Products

	BRACAnalysis CDx	Tumor BRACAnalysis CDx	MYRIAD myChoice HRD	Tumor Panel	Immune Pathway
Sample	Blood	Tumor	Tumor	Tumor	Tumor
Biomarkers	*BRCA*1&2	Tumor *BRCA*1&2	Genome-wide assessment of DNA scar associated with DNA repair defects	80+ clinically actionable oncology genes identified by pharma partners	Pathway test to identify responders to immunotherapy
Intellectual Property	Database, process, bioinformatics	Database, process, bioinformatics	MYGN has IP on three proprietary technologies (LOH, TAI, LST)	Database, process, bioinformatics	Patent filed
Currently Marketed	FDA approved	Yes, marketed in Europe only	Early access launch for platinum	In research use with major pharma partners	In research use with major pharma partners

10% of Global Revenue From International Markets by FY20



EndoPredict Superior in Large Head-to-Head Study

TransATAC Study: 928 Patients

Study		EndoPredict (clin)	1st Generation Test
Node Negative Low Risk	10-year Mets	5.9%	5.3%
	Hazard ratio	3.92	3.72
Node Positive Low Risk	10-year Mets	5.0%	25.1%
	Hazard ratio	9.49	1.88
	% Intermediate	0%	>26%

*Data presented at San Antonio Breast Cancer Symposium in 2015 from the TransATAC cohort

Progress on International* Reimbursement

Growth Drivers

	YEAR	FY16	FY17	FY18	FY19	FY20
REFERENCE	Hereditary Cancer					
	Tumor BRACAnalysis CDx	Linked to Lynparza				
	myChoice HRD			First PARP using HRD		
KIT	EndoPredict	Germany PMI UK PMI Switzerland French Tender	Germany GBA UK NHS Canada France HAS			
	Prolaris	Switzerland UK PMI	Germany PMI	Germany GBA UK NHS Canada France HAS		
	myPath Melanoma			Germany PMI UK PMI	Germany GBA Canada Switzerland France HAS	

No Reimbursement Low Reimbursement Broad Reimbursement

* EU6 and Canada

Fiscal Second Quarter 2016 Revenue By Product

(in millions)

Product	2Q16	2Q15	YoY Growth
Hereditary Cancer	$166.6	$165.0	1%
Vectra DA	$11.3	$10.8	5%
Prolaris	$1.9	$0.4	375%
Other	$2.8	$3.0	(7%)
Total Molecular Diagnostic Revenue	**$182.6**	**$179.2**	**2%**
Pharmaceutical & Clinical Services	$10.7	$5.2	106%
Total Revenue	**$193.3**	**$184.4**	**5%**

Fiscal Second Quarter Financial Results

(in millions except per share data)	2Q16	2Q15	YoY Growth
Total Revenue	**$193.3**	**$184.4**	**5%**
Gross Profit	$152.7	$146.5	4%
Gross Margin	79.0%	79.5%	NA
Operating Income	$45.2	$36.3	25%
Adjusted Operating Income	$48.4	$43.8	11%
Adjusted Operating Margin	25.0%	23.7%	NA
Net Income	$30.3	$24.0	26%
Diluted EPS	$0.41	$0.32	28%
Adjusted EPS	**$0.45**	**$0.40**	**13%**

3Q16 and FY16 Financial Guidance

Metric	Fiscal Year 2016	Fiscal Third Quarter 2016
Revenue	$750 to $770 million	$183 to $185 million
Diluted EPS	$1.48 to $1.53	$0.33 to $0.35
Adjusted EPS	$1.63 to $1.68	$0.37 to $0.39

Revenue Drivers in the Second Half of Fiscal Year 2016